Destination known: Targeted drug delivery in atherosclerosis and thrombosis

Drug Development Research

Volumn 74, Issue 7, 2013, Pages 460-471

  Westein, Erik ^a   Flierl, Ulrike ^a   Hagemeyer, Christoph E ^a   Peter, Karlheinz ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

atherosclerosis; targeted drug delivery; thrombosis

Indexed keywords

ALTEPLASE; CD39 ANTIGEN; CELECOXIB; FUMAGILLIN; HIRUDIN; LIPOSOME; MEVINOLIN; MICRORNA; NANOPARTICLE; POLYPEPTIDE; RAPAMYCIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; TANSHINONE; TICK ANTICOAGULANT PEPTIDE; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN;

ATHEROSCLEROSIS; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; PATHOGENESIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS;

EID: 84886442909     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21103     Document Type: Review

References (124)

1. Akagi D, Oba M, Koyama H, Nishiyama N, Fukushima S, Miyata T, Nagawa H, Kataoka K,. 2007. Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation. Gene Ther 14: 1029-1038.
2. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, et al. 2012. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60: 193-199.
3. Alzaraa A, Gravante G, Chung WY, Al-Leswas D, Bruno M, Dennison AR, Lloyd DM,. 2012. Targeted microbubbles in the experimental and clinical setting. Am J Surg 204: 355-366.
4. An F, Drummond DC, Wilson S, Kirpotin DB, Nishimura SL, Broaddus VC, Liu B,. 2008. Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther 7: 569-578.
5. Antithrombotic-Trialists'-collaboration. 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86.
6. Armstrong PC, Peter K,. 2012. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again. Thromb Haemost 107: 808-814.
7. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, et al. 2013. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 368: 1379-1387.
8. Assmann G, Gotto AM, Jr,. 2004. HDL cholesterol and protective factors in atherosclerosis. Circulation 109: III8-II14.
9. Baker AH,. 2004. Designing gene delivery vectors for cardiovascular gene therapy. Prog Biophys Mol Biol 84: 279-299.
10. Barenholz Y,. 2012. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J Control Release 160: 117-134.
11. Bitounis D, Fanciullino R, Iliadis A, Ciccolini J,. 2012. Optimizing druggability through liposomal formulations: new approaches to an old concept. ISRN Pharmaceutics 2012 (739432): 1-11.
12. Boilard E, Blanco P, Nigrovic PA,. 2012. Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol 8: 534-542.
13. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K, et al. 2009. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324: 1710-1713.
14. Brewer HB, Jr,. 2011. Clinical review: the evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab 96: 1246-1257.
15. Broz P, Marsch S, Hunziker P,. 2007. Targeting of vulnerable plaque macrophages with polymer-based nanostructures. Trends Cardiovasc Med 17: 190-196.
16. Caroli A, Cardillo MT, Galea R, Biasucci LM,. 2013. Potential Therapeutic role of microRNAs in ischemic heart disease. J Cardiol 61: 315-320.
17. Chen YC, Hagemeyer CE, Peter K,. 2013. A novel mouse model of atherosclerotic plaque instability for drug testing and mechanistic/therapeutic discoveries using gene and microRNA expression profiling. Circ Res 113: 252-265.
18. Chen ZY, Liang K, Qiu RX, Luo LP,. 2011. Ultrasound- and liposome microbubble-mediated targeted gene transfer to cardiomyocytes in vivo accompanied by polyethylenimine. J Ultrasound Med 30: 1247-1258.
19. Chistiakov DA, Sobenin IA, Orekhov AN,. 2012. Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular pathology. Drug Deliv 19: 392-405.
20. Chnari E, Lari HB, Tian L, Uhrich KE, Moghe PV,. 2005. Nanoscale anionic macromolecules for selective retention of low-density lipoproteins. Biomaterials 26: 3749-3758.
21. Chnari E, Nikitczuk JS, Uhrich KE, Moghe PV,. 2006. Nanoscale anionic macromolecules can inhibit cellular uptake of differentially oxidized LDL. Biomacromolecules 7: 597-603.
22. Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, Sood AK, Afshar-Kharghan V,. 2012. Platelets increase the proliferation of ovarian cancer cells. Blood 120: 4869-4872.
23. Cyrus T, Zhang H, Allen JS, Williams TA, Hu G, Caruthers SD, Wickline SA, Lanza GM,. 2008. Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol 28: 820-826.
24. Danila D, Partha R, Elrod DB, Lackey M, Casscells SW, Conyers JL,. 2009. Antibody-labeled liposomes for CT imaging of atherosclerotic plaques: in vitro investigation of an anti-ICAM antibody-labeled liposome containing iohexol for molecular imaging of atherosclerotic plaques via computed tomography. Texas Heart Institute Journal / (from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital) 36: 393-403.
25. Davignon J, Ganz P,. 2004. Role of endothelial dysfunction in atherosclerosis. Circulation 109: III27-III32.
26. Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, Ziemann M, Helbing T, El-Osta A, Jowett JB, et al. 2012. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res 93: 633-644.
27. Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X, Wang D, Krall TJ, Delphin ES, Zhang C,. 2009. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 284: 29514-29525.
28. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, et al. 2007. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta 1768: 1367-1377.
29. Eisenhardt SU, Schwarz M, Bassler N, Peter K,. 2007a. Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules. Nat Protoc 2: 3063-3073.
30. Eisenhardt SU, Schwarz M, Schallner N, Soosairajah J, Bassler N, Huang D, Bode C, Peter K,. 2007b. Generation of activation-specific human anti-alphaMbeta2 single-chain antibodies as potential diagnostic tools and therapeutic agents. Blood 109: 3521-3528.
31. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, et al. 2006. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3: 87-98.
32. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, Galuppo P, Kneitz S, Pena JT, Sohn-Lee C, et al. 2011. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124: 720-730.
33. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, et al. 2012. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 126: 3097-3137.
34. Fox JL,. 2003. US authorities uphold suspension of SCID gene therapy. Nat Biotechnol 21: 217.
35. Fujii H, Sun Z, Li SH, Wu J, Fazel S, Weisel RD, Rakowski H, Lindner J, Li RK,. 2009. Ultrasound-targeted gene delivery induces angiogenesis after a myocardial infarction in mice. JACC. Cardiovasc Imaging 2: 869-879.
36. Fujii H, Li SH, Wu J, Miyagi Y, Yau TM, Rakowski H, Egashira K, Guo J, Weisel RD, Li RK,. 2011. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Eur Heart J 32: 2075-2084.
37. Gaffney MM, Hynes SO, Barry F, O'Brien T,. 2007. Cardiovascular gene therapy: current status and therapeutic potential. Br J Pharmacol 152: 175-188.
38. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, et al. 2013. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127: 143-152.
39. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR,. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707-714.
40. Gu X, Zhang W, Liu J, Shaw JP, Shen Y, Xu Y, Lu H, Wu Z,. 2011. Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells. AAPS PharmSciTech 12: 1200-1208.
41. Gunawan RC, Auguste DT,. 2010. Immunoliposomes that target endothelium in vitro are dependent on lipid raft formation. Mol Pharm 7: 1569-1575.
42. Hagemeyer CE, Tomic I, Jaminet P, Weirich U, Bassler N, Schwarz M, Runge MS, Bode C, Peter K,. 2004. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide. Thromb Haemost 92: 47-53.
43. Hagemeyer CE, Muhlen C, von Elverfeldt D, Peter K,. 2009. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost 101: 1012-1019.
44. Hamilton A, Huang SL, Warnick D, Stein A, Rabbat M, Madhav T, Kane B, Nagaraj A, Klegerman M, MacDonald R, et al. 2002. Left ventricular thrombus enhancement after intravenous injection of echogenic immunoliposomes: studies in a new experimental model. Circulation 105: 2772-2778.
45. Hamilton AJ, Huang SL, Warnick D, Rabbat M, Kane B, Nagaraj A, Klegerman M, McPherson DD,. 2004. Intravascular ultrasound molecular imaging of atheroma components in vivo. J Am Coll Cardiol 43: 453-460.
46. Hamzah J, Kotamraju VR, Seo JW, Agemy L, Fogal V, Mahakian LM, Peters D, Roth L, Gagnon MK, Ferrara KW, et al. 2011. Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 108: 7154-7159.
47. Hansson GK, Libby P,. 2006. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6: 508-519.
48. Heidt T, Deininger F, Peter K, Goldschmidt J, Pethe A, Hagemeyer CE, Neudorfer I, Zirlik A, Weber WA, Bode C, et al. 2011. Activated platelets in carotid artery thrombosis in mice can be selectively targeted with a radiolabeled single-chain antibody. PLoS ONE 6: e18446.
49. Hohmann JD, Wang X, Krajewski S, Selan C, Haller CA, Straub A, Chaikof EL, Nandurkar HH, Hagemeyer CE, Peter K,. 2013. Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding? Blood 121: 3067-3075.
50. Holme MN, Fedotenko IA, Abegg D, Althaus J, Babel L, Favarger F, Reiter R, Tanasescu R, Zaffalon PL, Ziegler A, et al. 2012. Shear-stress sensitive lenticular vesicles for targeted drug delivery. Nat Nanotechnol 7: 536-543.
51. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K,. 2003. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9: 61-67.
52. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, et al. 2013. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31: 1157-1163.
53. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, Golub TR, Pieske B, Pu WT,. 2007. Altered microRNA expression in human heart disease. Physiol Genomics 31: 367-373.
54. Immordino ML, Dosio F, Cattel L,. 2006. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1: 297-315.
55. Iverson NM, Sparks SM, Demirdirek B, Uhrich KE, Moghe PV,. 2010. Controllable inhibition of cellular uptake of oxidized low-density lipoprotein: structure-function relationships for nanoscale amphiphilic polymers. Acta Biomater 6: 3081-3091.
56. Janthur WD, Cantoni N, Mamot C,. 2012. Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. Int J Mol Sci 13: 16020-16045.
57. Jelovac D, Emens LA,. 2013. HER2-directed therapy for metastatic breast cancer. Oncology 27: 166-175.
58. Kagaya H, Oba M, Miura Y, Koyama H, Ishii T, Shimada T, Takato T, Kataoka K, Miyata T,. 2012. Impact of polyplex micelles installed with cyclic RGD peptide as ligand on gene delivery to vascular lesions. Gene Ther 19: 61-69.
59. Kang DI, Lee S, Lee JT, Sung BJ, Yoon JY, Kim JK, Chung J, Lim SJ,. 2011. Preparation and in vitro evaluation of anti-VCAM-1-Fab'-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib. J Microencapsul 28: 220-227.
60. Kannel WB, McGee D, Gordon T,. 1976. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 38: 46-51.
61. Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, Lindner JR,. 2007. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation 116: 276-284.
62. Ko YT, Hartner WC, Kale A, Torchilin VP,. 2009. Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther 16: 52-59.
63. Korin N, Kanapathipillai M, Matthews BD, Crescente M, Brill A, Mammoto T, Ghosh K, Jurek S, Bencherif SA, Bhatta D, et al. 2012. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science 337: 738-742.
64. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M,. 2005. Silencing of microRNAs in vivo with "antagomirs". Nature 438: 685-689.
65. Langer HF, Choi EY, Zhou H, Schleicher R, Chung KJ, Tang Z, Gobel K, Bdeir K, Chatzigeorgiou A, Wong C, et al. 2012. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 110: 1202-1210.
66. Lehrman S,. 1999. Virus treatment questioned after gene therapy death. Nature 401: 517-518.
67. Leung K,. 2004a. Anti-ligand-induced binding sites (LIBS) antibody conjugated to microparticles of iron oxide. Bethesda, MD: Molecular Imaging and Contrast Agent Database (MICAD).
68. Leung K,. 2004b. Anti-ligand-induced binding sites (LIBS) single-chain antibody conjugated to microbubbles. Bethesda, MD: Molecular Imaging and Contrast Agent Database (MICAD).
69. Lewis DR, Kamisoglu K, York AW, Moghe PV,. 2011. Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis. Wiley interdisciplinary reviews. Nanomed Nanobiotechnol 3: 400-420.
70. Libby P, Ridker PM, Maseri A,. 2002. Inflammation and atherosclerosis. Circulation 105: 1135-1143.
71. Libby P, Ridker PM, Hansson GK,. 2011. Progress and challenges in translating the biology of atherosclerosis. Nature 473: 317-325.
72. Liu X, Cheng Y, Zhang S, Lin Y, Yang J, Zhang C,. 2009. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 104: 476-487.
73. Liu X, Suo R, Xiong SL, Zhang QH, Yi GH,. 2013. HDL drug carriers for targeted therapy. Clin Chim Acta 415: 94-100.
74. Ma YH, Wu SY, Wu T, Chang YJ, Hua MY, Chen JP,. 2009. Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles. Biomaterials 30: 3343-3351.
75. Marquart TJ, Allen RM, Ory DS, Baldan A,. 2010. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A 107: 12228-12232.
76. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, et al. 2002. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196: 887-896.
77. McCarthy JR, Korngold E, Weissleder R, Jaffer FA,. 2010. A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small 6: 2041-2049.
78. Messerschmidt SK, Kolbe A, Muller D, Knoll M, Pleiss J, Kontermann RE,. 2008. Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling. Bioconjug Chem 19: 362-369.
79. Messerschmidt SK, Musyanovych A, Altvater M, Scheurich P, Pfizenmaier K, Landfester K, Kontermann RE,. 2009. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J Control Release 137: 69-77.
80. Michelson AD,. 2010. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 9: 154-169.
81. Mondoro TH, Wall CD, White MM, Jennings LK,. 1996. Selective induction of a glycoprotein IIIa ligand-induced binding site by fibrinogen and von Willebrand factor. Blood 88: 3824-3830.
82. Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, Carberry J, Fouras A, Jackson SP,. 2009. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 15: 665-673.
83. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, et al. 2013. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61: e78-140.
84. Olejniczak M, Polak K, Galka-Marciniak P, Krzyzosiak WJ,. 2011. Recent advances in understanding of the immunological off-target effects of siRNA. Curr Gene Ther 11: 532-543.
85. Peter K, Graeber J, Kipriyanov S, Zewe-Welschof M, Runge MS, Kubler W, Little M, Bode C,. 2000. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation 101: 1158-1164.
86. Peters D, Kastantin M, Kotamraju VR, Karmali PP, Gujraty K, Tirrell M, Ruoslahti E,. 2009. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A 106: 9815-9819.
87. Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM,. 2012. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol 30: 3921-3923.
88. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, Ray TD, Sheedy FJ, Goedeke L, Liu X, et al. 2011. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478: 404-407.
89. Ross R,. 1999. Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
90. Sawant RR, Torchilin VP,. 2012. Challenges in development of targeted liposomal therapeutics. AAPS J 14: 303-315.
91. Schwarz M, Katagiri Y, Kotani M, Bassler N, Loeffler C, Bode C, Peter K,. 2004a. Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther 308: 1002-1011.
92. Schwarz M, Rottgen P, Takada Y, Le Gall F, Knackmuss S, Bassler N, Buttner C, Little M, Bode C, Peter K,. 2004b. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB journal: official publication of the Federation of American Societies for. Exp Biol 18: 1704-1706.
93. Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, Hagemeyer CE, Ahrens I, Moran N, Kenny D, et al. 2006. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res 99: 25-33.
94. Scott RC, Rosano JM, Ivanov Z, Wang B, Chong PL, Issekutz AC, Crabbe DL, Kiani MF,. 2009. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J 23: 3361-3367.
95. Shah PK,. 2007. High-density lipoprotein mimetics: focus on synthetic high-density lipoprotein. Am J Cardiol 100: S62-S67.
96. Sievers EL, Senter PD,. 2013. Antibody-drug conjugates in cancer therapy. Annu Rev Med 64: 15-29.
97. Stoll P, Bassler N, Hagemeyer CE, Eisenhardt SU, Chen YC, Schmidt R, Schwarz M, Ahrens I, Katagiri Y, Pannen B, et al. 2007. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol 27: 1206-1212.
98. Su CH, Wu YJ, Wang HH, Yeh HI,. 2012. Nonviral gene therapy targeting cardiovascular system. Am J Physiol Heart Circ Physiol 303: H629-H638.
99. Ta HT, Prabhu S, Leitner E, Jia F, von Elverfeldt D, Jackson KE, Heidt T, Nair AK, Pearce H, von Zur Muhlen C, et al. 2011. Enzymatic single-chain antibody tagging: a universal approach to targeted molecular imaging and cell homing in cardiovascular disease. Circ Res 109: 365-373.
100. Ta HT, Peter K, Hagemeyer CE,. 2012. Enzymatic antibody tagging: toward a universal biocompatible targeting tool. Trends Cardiovasc Med 22: 105-111.
101. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, et al. 2008. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980-984.
102. Tilemann L, Ishikawa K, Weber T, Hajjar RJ,. 2012. Gene therapy for heart failure. Circ Res 110: 777-793.
103. Topcic D, Kim W, Holien JK, Jia F, Armstrong PC, Hohmann JD, Straub A, Krippner G, Haller CA, Domeij H, et al. 2011. An activation-specific platelet inhibitor that can be turned on/off by medically used hypothermia. Arterioscler Thromb Vasc Biol 31: 2015-2023.
104. Torchilin VP,. 2004. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci 61: 2549-2559.
105. Torchilin VP,. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145-160.
106. Verma DD, Levchenko TS, Bernstein EA, Mongayt D, Torchilin VP,. 2006. ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model. J Drug Target 14: 273-280.
107. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, et al. 2012. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367: 1783-1791.
108. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT,. 2011. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13: 423-433.
109. Villanueva FS,. 2009. Ultrasound mediated destruction of DNA-loaded microbubbles for enhancement of cell-based therapies: new promise amidst a confluence of uncertainties? JACC. Cardiovasc Imaging 2: 880-882.
110. von zur Muhlen C, von Elverfeldt D, Moeller JA, Choudhury RP, Paul D, Hagemeyer CE, Olschewski M, Becker A, Neudorfer I, Bassler N, et al. 2008. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 118: 258-267.
111. Wang X, Hagemeyer CE, Hohmann JD, Leitner E, Armstrong PC, Jia F, Olschewski M, Needles A, Peter K, Ahrens I,. 2012. Novel single-chain antibody-targeted microbubbles for molecular ultrasound imaging of thrombosis: validation of a unique noninvasive method for rapid and sensitive detection of thrombi and monitoring of success or failure of thrombolysis in mice. Circulation 125: 3117-3126.
112. Weber C, Noels H,. 2011. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17: 1410-1422.
113. Westein E, van der Meer AD, Kuijpers MJ, Frimat JP, van den Berg A, Heemskerk JW,. 2013. Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner. Proc Natl Acad Sci U S A 110: 1357-1362.
114. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, et al. 2006. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 26: 2103-2109.
115. Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM,. 2008. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC. Cardiovasc Imaging 1: 624-634.
116. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. 2007. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015.
117. Wootton DM, Alevriadou BR,. 2012. The shear stress of busting blood clots. N Engl J Med 367: 1361-1363.
118. Xie F, Lof J, Matsunaga T, Zutshi R, Porter TR,. 2009. Diagnostic ultrasound combined with glycoprotein IIb/IIIa-targeted microbubbles improves microvascular recovery after acute coronary thrombotic occlusions. Circulation 119: 1378-1385.
119. Yu B, Mao Y, Bai LY, Herman SE, Wang X, Ramanunni A, Jin Y, Mo X, Cheney C, Chan KK, et al. 2013. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 121: 136-147.
120. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, et al. 2011. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378: 1231-1243.
121. Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M,. 2012. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 93: 555-562.
122. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC,. 2008. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83: 761-769.
123. Zhang W, Dang S, Hong T, Tang J, Fan J, Bu D, Sun Y, Wang Z, Wisniewski T,. 2012. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood 120: 2889-2898.
124. Zhang WL, Gu X, Bai H, Yang RH, Dong CD, Liu JP,. 2010. Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug. Int J Pharm 391: 313-321.